Literature DB >> 21354240

Excipients in medicinal products used in gastroenterology as a possible cause of side effects.

Maria Grazia Ursino1, Elisabetta Poluzzi, Carla Caramella, Fabrizio De Ponti.   

Abstract

Although most adverse drug reactions are caused by the active substances, excipients may sometimes affect the safety profile of a medicinal product. The aim of this review is twofold: (1) To identify the excipients most frequently contained in oral medicinal products marketed in Italy for gastrointestinal indications, and to evaluate the main safety concerns, considering both intrinsic toxicity and patient-related risk factors. (2) To analyze possible differences with medicinal products marketed in the United Kingdom and USA in terms of excipients and relevant warnings reported in the label. We identified excipients with potential impact on safety profile and calculated frequency of use of each identified excipient in 98 selected medicinal products. We discussed possible safety concerns in clinical practice. We also analyzed US and UK Summary of Products Characteristics (SmPC) of oral gastrointestinal products by searching in appropriate collections of regulatory agencies. Eleven excipients with a safety impact were identified (sucrose, saccharin, aspartame, sorbitol, mannitol, lactose, ethanol, propylene glycol, parabens, menthol and silica) and no substantial differences were found between drugs marketed in the three countries concerning excipient content. Warnings were more detailed in the SmPC of UK or USA products rather than Italian products. Information about pharmaceutical excipients with known effects is important in clinical practice, but the frequent lack of details in the related section of the SmPCs makes it difficult for health professionals to provide relevant advice. The availability of alternative products of the same therapeutic class, but lacking specific excipient(s) should be considered in selected patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354240     DOI: 10.1016/j.yrtph.2011.02.010

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  17 in total

1.  Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers.

Authors:  Ramin Mohammadzadeh; Behzad Baradaran; Hadi Valizadeh; Bahman Yousefi; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2014-02-07

2.  Effect of excipients on acetaminophen metabolism and its implications for prevention of liver injury.

Authors:  Michael Ganetsky; Mark Böhlke; Luis Pereira; David Williams; Barbara LeDuc; Shiva Guatam; Steven D Salhanick
Journal:  J Clin Pharmacol       Date:  2013-02-22       Impact factor: 3.126

3.  Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm.

Authors:  Manish Saxena; Sotiris Antoniou; Nadya Hamedi; Paul Robinson; Harjit Singh; Omar Mukhtar; Vikas Kapil; Melvin D Lobo
Journal:  Br J Gen Pract       Date:  2016-04       Impact factor: 5.386

Review 4.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

5.  Hospitalised neonates in Estonia commonly receive potentially harmful excipients.

Authors:  Jana Lass; Kaisa Naelapää; Utpal Shah; Ruth Käär; Heili Varendi; Mark A Turner; Irja Lutsar
Journal:  BMC Pediatr       Date:  2012-08-29       Impact factor: 2.125

6.  Structural and Functional Analysis of the Complex between Citrate and the Zinc Peptidase Carboxypeptidase A.

Authors:  Daniel Fernández; Ester Boix; Irantzu Pallarès; Francesc X Avilés; Josep Vendrell
Journal:  Enzyme Res       Date:  2011-07-25

7.  Application and Characterization of Gum from Bombax buonopozense Calyxes as an Excipient in Tablet Formulation.

Authors:  Ndidi C Ngwuluka; Jehu Kyari; John Taplong; Onyinye J Uwaezuoke
Journal:  Pharmaceutics       Date:  2012-08-03       Impact factor: 6.321

8.  In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2.

Authors:  Chengliang Zhang; Yanjiao Xu; Qiaoni Zhong; Xiping Li; Ping Gao; Chengyang Feng; Qian Chu; Yuan Chen; Dong Liu
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

9.  Evaluation of the Antibacterial Potential of Liquid and Vapor Phase Phenolic Essential Oil Compounds against Oral Microorganisms.

Authors:  Tong-Hong Wang; Shih-Min Hsia; Chi-Hao Wu; Shun-Yao Ko; Michael Yuanchien Chen; Yin-Hua Shih; Tzong-Ming Shieh; Li-Chuan Chuang; Ching-Yi Wu
Journal:  PLoS One       Date:  2016-09-28       Impact factor: 3.240

10.  Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm.

Authors:  Sotiris Antoniou; Manish Saxena; Nadya Hamedi; Catherine de Cates; Sakib Moghul; Satnam Lidder; Vikas Kapil; Melvin D Lobo
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-26       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.